# Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics

> **NCT01308437** · PHASE3 · TERMINATED · sponsor: **Wockhardt** · enrollment: 134 (actual)

## Conditions studied

- Type I Diabetes

## Interventions

- **BIOLOGICAL:** Wosulin (N or 70/30 with R)
- **BIOLOGICAL:** Novolin® (N or 70/30 with R)

## Key facts

- **NCT ID:** NCT01308437
- **Lead sponsor:** Wockhardt
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-03
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 134 (ACTUAL)
- **Why stopped:** Business reasons
- **Last updated:** 2023-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01308437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01308437, "Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01308437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*